Ku et al1 cite the findings of the Renal Outcomes With Telmisartan, Ramipril, or Both, in People at High Vascular Risk (ONTARGET) trial2 in arguing against dual renin-angiotensin system (RAS) inhibition in chronic kidney disease. However, the ONTARGET trial evaluated patients with less than 1 g of proteinuria, many of whom were normotensive. This was not a study of patients for whom nephrologists typically consider dual RAS inhibition; ONTARGET does not address, much less rebut, the efficacy of dual RAS inhibition that has been demonstrated in the hypertensive, proteinuric cohort.3
Hirsch S. The Case for Dual Renin-Angiotensin System Inhibition. Arch Intern Med. 2009;169(20):1931. doi:10.1001/archinternmed.2009.406
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.